MedBulletinsAura Celeste
Pediatrics

Monthly pediatrics bulletin — November 13, 2026

🎧 Listen to this issueAudio newscast · 5:54 min

This issue covers October 14 through November 13, 2026. The month was dominated by two safety signals (newborn vitamin K and gene therapy for spinal muscular atrophy) and by a region, the Americas, that has now passed 57,000 measles cases this year. We include 10 items verified at the source.

Neonatology

1. Nonreceipt of intramuscular vitamin K at birth is associated with 47% more bleeding and 2.4 times more intracranial hemorrhage

[Publication] [United States]
National retrospective cohort in JAMA (November 5) using electronic health record data (Epic Cosmos) on 5,240,780 infants born at 35 to 43 weeks between 2017 and 2025. The exposure is recorded nonreceipt of intramuscular vitamin K, not demonstrated parental refusal. Nonreceipt rose from 3.1% in 2017 to 6.8% in 2025 (234,825 nonrecipients over the whole period, 4.5%). Bleeding by 6 months was 288.0 vs 185.9 per 10,000 (adjusted risk ratio 1.47; 95% CI 1.43-1.51; adjusted number needed to harm: 114, not derived directly from the crude difference); intracranial bleeding 33.0 vs 13.2 per 10,000 (adjusted RR 2.43; 95% CI 2.26-2.62); and death with concurrent bleeding during the birth hospitalization 2.9 vs 1.1 per 10,000 (adjusted RR 2.69; 95% CI 2.09-3.47).
Why it matters: it is observational and shows association, not causation; some "nonrecipients" may have received oral or delayed vitamin K, not every case of nonreceipt is a parental refusal, and coding bias may inflate the estimates. Even so, the magnitude, biological plausibility and sample size make it a strong numerical argument for the conversation with families who are hesitant about the injection.

Sources

2. Cash transfers to pregnant women and infants: neonatal mortality in Flint fell by half

[Publication] [United States]
Research letter in JAMA Pediatrics (doi 10.1001/jamapediatrics.2026.4943), published on November 2 and released by Michigan State University on November 3, on Flint, Michigan, and Rx Kids, a program that provides unconditional cash during pregnancy and the first year of life and began in January 2024. Using state birth and death records from 2021 to 2025, Flint's 2025 neonatal mortality rate (5.1 per 1,000 live births) was compared with its 2021-2024 rate (10.2), a period that includes 2024, the program's first year (−50%); early neonatal mortality went from 7.9 to 2.0 (−74%), while neonatal mortality in the rest of Michigan stayed at 4.0-3.9; for the first time in the study period, the differences with the rest of the state were no longer statistically significant.
Why it matters: similar results (5.1 per 1,000 in 2025) had been released as a preprint in June 2026, according to Michigan Public; what is new in this period is the peer-reviewed publication. It compares a single year (2025) with a reference period that already includes the program's first year; these are population data from a small city with few events per year, vulnerable to regression to the mean and to concurrent interventions, so causality is not established. Even so, for countries with persistently high neonatal mortality, it is a reminder that part of the problem is not solved in the neonatal unit but in household income.

Sources

Infectious diseases, vaccines and emergency care

3. Measles in the Americas: 57,666 cases and 81 deaths in 2026

[Epidemiological alert] [Americas]
PAHO Situation Report No. 15 (dated November 5 and published November 6) counts 57,666 confirmed measles cases in 17 countries and territories through epidemiological week 43, 4.7 times the same period of 2025, with 81 deaths (Guatemala 53, Mexico 23, United States 3, Peru 1, Bolivia 1). Five countries account for 99.5% of cases: Guatemala 34,748, Mexico 13,761, United States 4,852, Peru 2,862 and Canada 1,126. In weeks 41-42, 547 new cases were reported, 38% fewer than in weeks 39-40 (885).
Why it matters: the Dominican Republic does not appear among countries with cases in this report, but it receives tourists and migrants from the five most affected; checking two MMR doses at every contact and thinking of measles in any febrile rash is now a clinical obligation.

Sources

4. Carbapenemase-producing Enterobacterales in children: incidence nearly doubled in the United States, with NDM now dominant

[Publication] [United States]
CDC-led surveillance analysis published in the Journal of the Pediatric Infectious Diseases Society on November 4 (doi 10.1093/jpids/piag115). Between 2019 and 2024, 1,845 carbapenem-resistant Enterobacterales cases were recorded in 1,753 children under 18 (median age 5, according to Contemporary Pediatrics coverage); estimated national incidence rose 51% (IRR 1.51; 95% CI 1.22-1.88) and that of carbapenemase producers 92% (IRR 1.92; 95% CI 1.25-2.99), with a more than fourfold increase in NDM (IRR 4.24; 95% CI 2.07-9.16), which overtook KPC. Infants had the highest rates. In chart review of 109 of 129 children with carbapenemase producers, only 14% had no healthcare risk factors; 40% had been in intensive care and 37% had received healthcare outside the United States.
Why it matters: this is a convenience sample with unadjusted rates in an accepted manuscript, so the figures may shift, but the increase was similar in the 29-state open cohort. NDM identification should guide susceptibility testing and pediatric infectious diseases review: ceftazidime-avibactam alone does not cover NDM, and alternatives depend on susceptibility, infection site, age, and availability. Given that some cases are linked to healthcare abroad, Dominican hospitals receiving international transfers should review their admission screening policy.

Sources

5. Pfizer's 25-valent pneumococcal conjugate vaccine: responses to all 25 serotypes in infants (phase 2)

[Industry] [Congress] [United States]
Data presented at IDWeek 2026 on October 24 (NCT06524414): a phase 2 trial in healthy infants against PCV20, with four doses (at 2, 4, 6 and 12-15 months and randomized, according to Contemporary Pediatrics coverage). The candidate adds serotypes 15A, 23A, 23B, 24F and 35B. Responses were seen for all 25 serotypes after the third and fourth doses; for serotype 3, geometric mean concentrations were about 8.8-fold higher than PCV20 after dose 3 and about 15-fold after dose 4. Local reactions, systemic events and adverse events were balanced between groups, with no related serious adverse events. Three phase 3 trials with up to 6,830 participants are already under way.
Why it matters: these are manufacturer-sponsored immunogenicity data with no sample size in the press release and no established correlate of protection for the five new serotypes, so they change no recommendation; the real interest is serotype 3, responsible for 10.6% of invasive pneumococcal disease in US children under five according to Pfizer, and historically poorly covered by conjugates. This is a signal of where the market is heading, not a clinical option.

Sources

6. More than half of household hepatitis B exposures in children under 5 do not come from the mother

[Congress] [United States]
Retrospective Kaiser Permanente Northern California cohort presented at IDWeek 2026 (Washington, October 21-24). Of more than 158,000 children under 5 in about 131,000 households, 2,024 lived with a person with active hepatitis B infection; in 58.2% of them (1,178) the infected contact was not the birth mother; these nonmaternal contacts were 76.5% male, with a median age of 44. Vaccination within 7 days of birth was 100% in infants of positive mothers, 93.5% in those exposed through other household members and 86.7% in the unexposed.
Why it matters: the finding speaks directly to the change voted by the US ACIP in 2025, which drops the universal birth-dose recommendation for infants of surface antigen-negative mothers and which, according to Healio, a federal judge has temporarily blocked; if household risk is mostly nonmaternal, prenatal screening is not enough. It is a conference abstract without peer-reviewed publication and the investigator reports research support from Pfizer, but it strengthens the case for keeping the birth dose.

Sources

General pediatrics, development, nutrition and adolescence

7. Air pollution and pediatric atopic dermatitis: meta-analysis of 52 studies

[Meta-analysis] [International]
Systematic review and meta-analysis in JAMA Pediatrics (November 9; doi 10.1001/jamapediatrics.2026.5020) of 52 observational studies from 17 countries. Per 10 µg/m³ increase, atopic dermatitis outpatient visits were associated with nitrogen dioxide (OR 3.46; 95% CI 1.06-11.31) and sulfur dioxide (OR 3.96; 1.00-15.65), at moderate certainty. PM2.5 and PM10 were probably associated with higher atopic dermatitis prevalence, at moderate certainty. Findings for incidence and severity were mixed or did not support an association.
Why it matters: the confidence intervals are very wide and the lower bounds brush the null, so the meta-analysis shows a probable association, not its magnitude; environmental context can be explored in the history; this meta-analysis does not establish an individual cause of refractory disease.

Sources

Pediatric surgery and subspecialties

8. FDA investigates tumors after gene therapy for spinal muscular atrophy (onasemnogene abeparvovec)

[Regulatory FDA] [United States]
FDA safety communication of November 6: the agency is investigating the identified risk of neoplasia, including malignancy, with serious outcomes in patients treated with Zolgensma. Three tumors were associated with the GLI1 oncogene; in two, tumor tissue analysis showed AAV vector DNA integrated into the host genome, with the vector promoter inserted upstream of or within GLI1; the mechanism in the third is still under investigation. Reported tumors involve the central and peripheral nervous system, spinal and paraspinal regions, and kidney. According to Novartis, as cited by Fierce Pharma, it has received nine tumor reports among more than 6,000 treated patients since first approval in 2019 (reports, not a calculated causal incidence). FDA maintains that benefits outweigh risks for approved uses, extends the risk to Itvisma (same vector and construct, no tumors reported) and asks that all treated patients be monitored for tumor formation.
Why it matters: molecular confirmation of vector integration turns AAV insertional oncogenesis into an identified risk, which changes informed consent and long-term follow-up for every treated child. It does not change the indication: untreated type 1 spinal muscular atrophy remains fatal.

Sources

9. EMA: positive opinion for weekly navepegritide in pediatric achondroplasia and negative opinion on extending gemtuzumab to pediatric AML

[Regulatory EMA] [European Union]
At its October 12-15 meeting (highlights published October 16), the CHMP recommended approval of Yuviwel (navepegritide), a once-weekly C-type natriuretic peptide prodrug, for the treatment of achondroplasia in children. At the same session it did not recommend extending Mylotarg (gemtuzumab ozogamicin) to children aged 1 to under 18 with newly diagnosed acute myeloid leukemia, although the study data will be added to the product information; it also confirmed, after re-examination, its refusal of Yartemlea (narsoplimab) for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Why it matters: navepegritide competes with daily vosoritide and its practical advantage is weekly dosing, but the pivotal trial measures growth velocity, not final height or complications (foramen magnum stenosis, apnea), which is what families care about. Regional access will depend on regulatory decisions, availability, and cost; a CHMP opinion is not yet a European Commission decision. The gemtuzumab refusal is a reminder that benefit in adults does not automatically transfer to children.

Sources

10. Living more than 60 miles from the surgical hospital is associated with longer stays and more complications in common pediatric surgery

[Publication] [United States]
Retrospective analysis of inpatient databases from 12 states (2018-2021) in the Journal of the American College of Surgeons (doi 10.1097/XCS.0000000000002208), released on November 10: 71,451 children undergoing appendectomy, cholecystectomy, pyloric stenosis repair, inguinal hernia repair or gastrostomy. The 8,594 (12%) living more than 60 miles away had 21% higher adjusted odds of complications than those within 30 miles, although the association lost significance after adjusting for state; length of stay was 13% longer and charges 9% higher. That group was younger (median 3 vs 10 years), more rural (47% vs 5%) and more often transferred (39% vs 13%).
Why it matters: an administrative database does not capture severity or complexity well, so the excess complications may reflect the type of patient who travels more than the travel itself; applicability to the Dominican Republic requires local data on access, transfers, and outcomes.

Sources

Upcoming meetings and dates

No meetings are included in this issue.

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.